赛生药业(06600.HK)受投资者热捧,上限定价获超额认购千倍
赛生药业(06600.HK)香港IPO发行价取招股区间上限18.8港元,公告显示,根据国际发售提呈发售的股份获大幅超额认购,相当于根据国际发售初步可供认购发售股份总数约【10】倍。根据香港公开发售初步提呈的香港发售股份获大幅超额认购。合共接获【436,000】份有效申请,认购合共【12,388,265,000】股,相当于根据香港公开发售初步可供认购香港发售股份总数约【1,068.05】倍,公司此次股票发行定价合理,受到市场追捧。
格隆汇据悉:该公司一家拥有产品和商业化集成平台的领先生物制药公司,已上市产品销售约20亿元规模,并持续取得较快增长;在研产品竞争优势突出,并处于热门靶点,未来几年内将接连落地。
根据公司招股书显示,2017年至2019年公司营业收入分别为12.13亿元、14.09亿元、17.08亿元,同比增长16.16%与21.22%。 2017年至2019年公司净利润分别为0.2亿元、5.35亿元、6.15亿元,同比增长2575%以及14.95%。截至2020年9月30日,公司净利润为6.90亿元,同比增长41.68%。
值得注意的是,在2020年疫情这一黑天鹅事件中,公司仍能够呈现出营业收入与净利润两者均高速增长的局面,良好的财务状况体现了业务内核的强劲支撑。此外,此次上市定价合理,值得进一步关注后市发展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.